August 29, 2018 10:06 AM EDT

Emergent snags opioid drug in $735M buyout deal; Germany frets about post-Brexit disruption in drug market

John Carroll

Editor & Founder

→ Emergent BioSolutions has struck a $735 million deal to acquire Adapt, which markets an opioid overdose drug called Narcan. Emergent is paying …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Emergent snags opioid drug in $735M buyout deal; Germany frets about post-Brexit disruption in drug market

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Small personalized vaccine trial sees progress in late-stage kidney cancer

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Bristol Myers, Kyowa Kirin disclose layoffs

Emer­gent snags opi­oid drug in $735M buy­out deal; Ger­many frets about post-Brex­it dis­rup­tion in drug mar­ket

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Emergent snags opioid drug in $735M buyout deal; Germany frets about post-Brexit disruption in drug market